Invesco Ltd. lessened its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 44.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,790,260 shares of the medical research company's stock after selling 1,426,191 shares during the period. Invesco Ltd. owned about 1.36% of Natera worth $283,398,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares during the period. Versant Capital Management Inc grew its position in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. lifted its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. Royal Bank of Canada initiated coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price on the stock. Sanford C. Bernstein boosted their target price on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. Morgan Stanley upped their price target on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. StockNews.com upgraded Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Finally, Barclays cut their target price on shares of Natera from $200.00 to $160.00 and set an "overweight" rating on the stock in a research note on Thursday. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $175.76.
Check Out Our Latest Research Report on NTRA
Natera Stock Up 0.3 %
Shares of NASDAQ:NTRA traded up $0.41 during midday trading on Monday, hitting $148.45. 887,252 shares of the company's stock traded hands, compared to its average volume of 1,394,376. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a market cap of $20.07 billion, a PE ratio of -84.35 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm's fifty day moving average price is $152.09 and its two-hundred day moving average price is $152.40.
Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Insider Activity
In other Natera news, insider Solomon Moshkevich sold 24,861 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the completion of the sale, the insider now owns 140,684 shares in the company, valued at $23,208,639.48. This trade represents a 15.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares in the company, valued at $29,160,963.60. This represents a 30.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 325,922 shares of company stock worth $51,603,664 over the last 90 days. Company insiders own 7.60% of the company's stock.
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
